Indehaveren af markedsføringstilladelsen var af den opfattelse, at alle MAO- hæmmere skulle være kontraindicerede sammen med venlafaxin.
However, the CHMP considered that only non-selective, irreversible MAOIs should be contraindicated and that a strong warning in Section 4.4 and Section 4.5 of the SPC should be sufficient for the reversible MAOIs.